Related by context. All words. (Click for frequent words.) 79 Phase Ib clinical 77 Phase Ib 77 phase IIa 76 Phase 1b clinical 75 Phase 1a 75 Phase IIa clinical 74 Phase 2a clinical 74 Phase 2b study 74 Phase 1a clinical 74 phase IIa clinical 74 Phase 2a trial 73 single ascending dose 73 phase IIb clinical 73 multiple ascending dose 73 Phase IIIb clinical 73 phase IIb 72 Phase 2a 72 Phase Ib II 72 Phase Ib study 72 Phase 1b 72 Phase IIa trial 72 dose escalation Phase 71 pharmacokinetic PK study 71 Phase 1b trial 71 dose escalation clinical 71 Phase III clinical 71 dose escalation trial 71 Phase IIb clinical 70 phase Ib 70 Phase 2b trial 70 Phase IIa 70 phase 2a 69 phase Ib clinical 69 placebo controlled Phase 69 Phase III 69 Phase #b/#a 69 Phase IIb 69 Phase 2b 68 LibiGel Phase III 68 Phase 2b clinical 68 multicenter Phase 68 GLP toxicology studies 68 IIa trial 68 Phase IIb trial 68 pharmacokinetics PK 68 MEND CABG 68 CRLX# 68 Phase IIa trials 68 Phase 2a clinical trials 68 Phase 2b clinical trials 68 Phase 1b clinical trials 68 ORMD 68 pivotal Phase III 67 IMA# 67 preclinical efficacy 67 randomized Phase 2b 67 dose escalation study 67 Phase IIb trials 67 Cloretazine ® 67 multicenter Phase II 67 multicenter clinical 67 INCB# [001] 67 R#/MEM # 67 randomized Phase III 67 alvespimycin 66 phase IIb study 66 oral ridaforolimus 66 Androxal TM 66 Phase II 66 Phase #/#a 66 APEX PD 66 Phase Ib clinical trials 66 BRIM3 66 randomized Phase IIb 66 multicenter randomized placebo controlled 66 randomized Phase 66 Phase #b/#a trial 66 pivotal bioequivalence 66 Phase IIB 66 Phase III randomized controlled 66 confirmatory Phase III 66 Phase IIIb 66 NOX E# 66 Phase #b/#a clinical 65 ascending dose 65 placebo controlled 65 clinical trial 65 VNP#M 65 ATL# [001] 65 multicentre randomized 65 RSD# oral 65 mertansine 65 elacytarabine 65 rALLy clinical trial 65 Plicera 65 GetGoal Phase III 65 budesonide foam 65 Ozarelix 65 ELACYT 65 multicenter phase 65 Cloretazine 65 Randomized Phase 65 YONDELIS 65 midstage trials 65 dose cohort 65 Initiate Phase 65 Phase IIb III 65 phase IIb III 65 pharmacokinetic PK 65 randomized controlled Phase 65 Phase III psoriasis 64 ascending doses 64 JAK inhibitor 64 IIa trials 64 double blinded placebo 64 Sym# 64 Cloretazine R VNP#M 64 Alzhemed TM 64 CR# vcMMAE 64 PRTX 64 pharmacodynamic PD 64 multicenter randomized controlled 64 phase IIIb 64 Phase IIA 64 dirucotide 64 FOLOTYN ® 64 blinded placebo controlled 64 phase IIb trial 64 lomitapide 64 PSMA ADC 64 assessing T DM1 64 pharmacodynamic effects 64 masked placebo controlled 64 PSN# [002] 64 blinded randomized placebo controlled 64 TG MV 64 placebo controlled Phase III 64 urocortin 2 64 ADVANCE PD 64 AVADO 64 Bezielle 64 treatment naive genotype 64 Phase III Pivotal 64 double blinded randomized 64 midstage clinical 64 IND submission 64 placebo controlled clinical 63 bevirimat Study 63 Phase Ib IIa 63 pharmacokinetic studies 63 CHAMPION PCI 63 KRN# 63 NP2 Enkephalin 63 IIa clinical 63 Phase 1b dose escalation 63 dosing cohort 63 pharmacokinetic PK profile 63 TMC# C# 63 ISIS # 63 ganetespib 63 MEK inhibitor 63 multicenter Phase III 63 dosing cohorts 63 tolevamer 63 pharmacokinetic 63 viral kinetic 63 placebo controlled randomized 63 HCV SPRINT 63 oral prodrug 63 Fx #A 63 TMC# [002] 63 elotuzumab 63 cannabinor 63 dose dose escalation 63 ongoing Phase 1b 63 Phase III clinical trials 63 PANVAC VF 63 TRO# 63 lead Aganocide compound 63 PHX# 63 vidofludimus 63 Initiated Phase 63 AEG# 63 GAMMAGARD 63 ataluren 63 Proellex TM 63 safety tolerability pharmacokinetic 63 Corlux 63 Combination REOLYSIN R 63 Testosterone MDTS ® 63 randomized blinded 63 VICTOR E1 63 rALLy trial 63 fostamatinib 63 Pimavanserin 63 Aryplase 63 HPTN 63 dose escalation phase 63 IND enabling 63 trastuzumab DM1 T DM1 63 LAB CGRP 63 Phase IIb clinical trials 63 lexidronam injection 63 TBC# 63 confirmatory Phase 3 63 Amrubicin 63 Phase III ADT 63 initiated Phase Ib 62 oral rivaroxaban 62 Annamycin 62 polymerase inhibitor 62 TASKi2 62 pharmacokinetics pharmacodynamics 62 Phase 2b kidney transplant 62 PEG PAL 62 fosbretabulin 62 Phase III pivotal 62 PRX # 62 galiximab 62 Omacetaxine 62 huC# DM4 62 TACI Ig 62 BRIM2 62 LUX Lung 62 tesmilifene 62 Alocrest 62 initiate Phase IIa 62 Ophena TM 62 DermaVir Patch 62 pharmacokinetic pharmacodynamic 62 multicenter randomized Phase 62 TOLAMBA 62 AIR CF1 62 APTIVUS 62 EDEMA3 62 unique alkylating agent 62 PREOS 62 Quinamed 62 PXD# 62 fidaxomicin Phase 3 62 velafermin 62 lintuzumab 62 glufosfamide 62 randomized placebo controlled 62 IIa clinical trial 62 pafuramidine 62 CoFactor 62 oral deforolimus 62 AKT inhibitor 62 PRT# 62 multicenter randomized 62 preclinical pharmacokinetic 62 Prodarsan ® 62 Azedra 62 Dacogen injection 62 pivotal Phase 62 thorough QT 62 initiate Phase 2b 62 Aurexis 62 XL# SAR# 62 HQK 62 ABSORB clinical 62 randomized multicentre 62 CB2 selective receptor agonist 62 OHR/AVR# 62 Phase 62 huN# DM1 62 HuMax EGFr 62 Zemplar Capsules 62 multicenter placebo controlled 62 MAGE A3 ASCI 62 selective androgen receptor modulator 62 HGS ETR1 62 forodesine 62 Urocidin 62 CEQ# 62 pharmacodynamics 62 initiate Phase 1b 62 antibody MAb 62 AVN# [001] 62 octreotide implant 62 MEND CABG II 62 ABSORB trial 62 Xanafide 62 trastuzumab emtansine T DM1 62 Allovectin 7 62 Tyrima 62 BNC# 62 adecatumumab MT# 62 CBLC# 62 AQ4N 62 farletuzumab 62 teduglutide 62 EOquin TM 62 dose escalation 61 Aflibercept 61 randomized multicenter 61 velafermin belinostat 61 satraplatin Phase 61 Phase III Clinical Trial 61 RE SURGE 61 Archexin 61 PDX pralatrexate 61 preclinical toxicology 61 PDE4 inhibitor 61 KNS # 61 CCX# 61 relapsed MM 61 REVIVE Diabetes 61 HspE7 61 randomized controlled 61 Phase III placebo controlled 61 LCP Tacro 61 ANCHOR trial 61 evaluating tivozanib 61 enzastaurin 61 CALGB # [002] 61 II Clinical Trial 61 rALLy 61 SPIRIT FIRST 61 nucleotide analog 61 Traficet EN 61 riociguat 61 Prosaptide 61 initiate Phase IIb 61 Phase IIIb study 61 NO# [002] 61 OncoVEX GM CSF 61 registrational 61 Pivotal Phase III 61 Phase III confirmatory 61 CLARITY study 61 BioNumerik 61 pomalidomide 61 SUCCEED trial 61 treatment naïve genotype 61 AIM HIGH 61 Neuradiab 61 orally bioavailable 61 TEMSO 61 GLPG# 61 multicenter randomized double 61 PS# [001] 61 ARRY 61 Sapacitabine 61 Allovectin 7 R 61 ToGA 61 compound INCB# 61 torezolid phosphate 61 pertuzumab 61 liposomal formulation 61 axitinib 61 Phase IIa clinical trials 61 confirmatory clinical 61 EOquin 61 Aplidin 61 lumiliximab 61 PEG SN# 61 Fibrillex TM 61 CTAP# Capsules 61 lorvotuzumab mertansine 61 randomized clinical 61 COU AA 61 Glufosfamide 61 AERAS-#/Crucell Ad# 61 controlled multicenter 61 Dacogen decitabine 61 Board DSMB 61 EndoTAG TM -1 61 monoclonal antibody conjugated 61 MBP# [001] 61 intranasal formulation 61 ILLUMINATE 61 GRNVAC1 61 Virulizin ® 61 NGX# 61 PNT# 61 AEGR 61 Phenoptin 61 IMPACT DCM 61 ENDEAVOR III 61 Phase 2b Clinical Trial 61 Phase lll 61 clinical pharmacology studies 61 SNT MC# 61 ZACTIMA 61 Degarelix 61 prospective randomized multicenter 61 PEARL SC 61 Phase III trials 61 HGS ETR2 61 Cannabinor 61 PRE SURGE 61 nonclinical studies 61 davunetide intranasal AL 61 Prodarsan 61 dirucotide MBP# 61 crizotinib PF # 61 virus HCV protease inhibitor 61 PRESEPT 61 neratinib 61 IIb clinical trial 61 ADAGIO study 61 Triapine R 60 Cloretazine R 60 Tezampanel 60 PLK1 SNALP 60 Dextofisopam 60 Elagolix 60 pharmacokinetic parameters 60 INSPIRE Trial Phase III 60 IMGN# 60 blind randomized placebo 60 orally dosed 60 blinded randomized 60 Aurora kinase inhibitor 60 CCR9 antagonist 60 Telatinib 60 BLA submission 60 LUMINATE 60 Tesetaxel 60 trodusquemine 60 randomized multicenter trial 60 LEVADEX ™ 60 RSD# 60 Randomized Phase II 60 EFAPROXYN 60 safety tolerability pharmacokinetics 60 Enobia 60 omacetaxine mepesuccinate 60 Daclizumab 60 randomized controlled multicenter 60 Maximum Tolerated Dose 60 Phase IIb Clinical Trial 60 dacetuzumab 60 UPLYSO 60 evaluating Actimmune 60 administered subcutaneously 60 RiVax 60 solithromycin 60 Asentar 60 #I TM# 60 GLYX 60 anticancer compound 60 eosinophilic asthma 60 CRMD# 60 teriflunomide 60 RGB # 60 evaluating mipomersen 60 ENDEAVOR IV 60 Spiegelmer ® 60 HGS# 60 oral methylnaltrexone 60 melphalan prednisone 60 IL# PE#QQR 60 registrational trial 60 GOUT 60 pitavastatin 60 MERLIN TIMI 60 Darinaparsin 60 Matrix Phase 2b 60 novel VDA molecule 60 clinical trials 60 designated HVTN 60 deforolimus 60 entinostat 60 Luteinizing Hormone Releasing Hormone 60 Triolex 60 Phase 2b monotherapy 60 inhaled AAT 60 QLT# 60 evaluating Prochymal 60 TLK# 60 double blind placebo 60 indibulin 60 GALNS 60 lenalidomide Revlimid R 60 pharmacodynamic profile 60 Multiple Ascending Dose 60 HCV RESPOND 2 60 OMP #M# 60 MGd 60 AZILECT R 60 OvaRex R 60 baminercept 60 non nucleoside inhibitor 60 BrachySil 60 GSK# [002] 60 ANTEGREN 60 Panzem R NCD 60 DDP# 60 tolerated dose MTD 60 seliciclib CYC# 60 Bicifadine 60 Omnitarg 60 PREOS R 60 BIM #A# 60 IMC #B 60 controlled dose escalation 60 IMPACT IMmunotherapy 60 preclinical 60 tolerability 60 safety tolerability 60 tanespimycin 60 phase III ACCLAIM 60 vivo toxicology 60 SAR# [004] 60 acyclovir Lauriad R 60 ThermoDox R 60 Tarceva TM 60 SYMMETRY trial 60 EDEMA4 60 Pivotal Phase 60 Capesaris 60 randomized double 60 Testosterone MDTS R 60 pharmacodynamics PD 60 AVE# 60 stated Michelle Berrey 60 metastatic hormone refractory 60 maximally tolerated dose 60 trastuzumab DM1 60 TELCYTA 60 mg/m2 cohort 60 sunitinib malate 60 Troxatyl 60 apricitabine ATC 60 trial evaluating PRX# 60 tramiprosate Alzhemed TM 60 CLIRS trial 60 EXPLORE Xa 60 CALGB 60 Tanespimycin 60 ruxolitinib 60 CCR5 antagonist 60 eniluracil 60 Pharmacokinetics PK 60 Phase III Psoriasis 60 Mipomersen 60 bardoxolone 60 oral picoplatin 60 reslizumab 60 NVA# 60 HER2 positive metastatic breast 60 Ophena 60 PA# [002] 60 hypoxia activated prodrug 60 Personalized Immunotherapy 60 BCIRG 60 EVIZON TM 60 Exherin TM 60 DEB# 60 Protexia ® 60 PROSTVAC VF 60 STRIDE PD 60 OvaRex ® MAb 60 viral kinetics 60 Phase IIb Trial 60 sitaxsentan 60 dyskinesia PD LID 59 PF # [002] 59 CTA# Injection 59 By JENNIFER LEARN 59 LymphoStat B TM 59 Novolimus 59 Phase III registrational 59 RhuDex ® 59 PRECiSE 59 Aptivus ® 59 MYDICAR ® 59 COMFORT II 59 EMPHASIS HF trial 59 Hyphanox 59 Laquinimod 59 prospective randomized placebo 59 HuMax CD4 59 RELOVAIR ™ 59 Silodosin 59 estramustine 59 bortezomib Velcade 59 BLA filing 59 Trofex 59 randomized multicenter Phase III 59 ALN VSP Phase 59 dose cohorts 59 mGluR5 NAM 59 Phase III randomized 59 PRIMO CABG 59 investigational HCV polymerase 59 Diamyd ® 59 subcutaneously administered 59 MORAb 59 CYT# potent vascular disrupting 59 favorable pharmacokinetic profile 59 ZYBRESTAT fosbretabulin 59 PFO migraine 59 LY# [003] 59 Anthim 59 investigational drug 59 pharmacokinetics 59 Phase 2b randomized 59 custirsen 59 ocrelizumab 59 NEBIDO 59 LCP AtorFen 59 Pharmacokinetic PK 59 Prostate Lung Colorectal 59 prucalopride 59 liprotamase 59 Vicriviroc 59 ALTU 59 MDV# 59 DASISION 59 nitazoxanide 59 relapsed multiple myeloma 59 Hsp# Inhibitor 59 rNAPc2 59 ELND# 59 HuMax CD# 59 candidate CRLX# 59 European Sepsis Trial 59 immunogenicity 59 SILENOR TM 59 PEG IFN 59 balsalazide tablet 59 eprotirome 59 RG# ITMN 59 thymalfasin 59 PI3K/Akt pathway inhibitor 59 mcg dose 59 CIMZIA TM certolizumab pegol 59 metastatic castration resistant 59 Aclidinium 59 TOCOSOL Paclitaxel 59 Telintra 59 CIMZIA ™ 59 interferon gamma 1b 59 Medidur TM FA 59 CAMPATH 59 glucokinase activator 59 TKB# 59 Phase IIB clinical 59 Phase III multicenter 59 IDX# 59 multicenter randomized clinical 59 blinatumomab 59 ritonavir boosted danoprevir 59 omega interferon 59 TAXUS ATLAS 59 SUVN 59 beta 1a 59 recurrent glioblastoma multiforme 59 registrational Phase 59 TASKi3 59 squalamine 59 unblinded 59 SinuNase ™ 59 rindopepimut 59 bicifadine 59 LE SN# 59 generation PNP inhibitor 59 Ereska 59 OncoGel 59 maturation inhibitor 59 RDEA# 59 relapsed refractory multiple myeloma 59 zanolimumab 59 multicenter prospective 59 lintuzumab SGN 59 methylnaltrexone 59 CDP# 59 Zybrestat 59 HCV protease inhibitor 59 Tesmilifene 59 Maximum Tolerated Dose MTD 59 brivaracetam 59 voreloxin 59 NSABP B 59 bepotastine besilate nasal spray 59 telomerase therapeutic 59 miconazole Lauriad ® 59 BETAS 59 refractory CLL 59 metaglidasen 59 pharmacokinetic profile 59 PENNVAX B 59 AIR CF2 59 Pyridorin TM 59 ACTEMRA TM 59 Prodarsan R 59 NN# [001] 59 metastatic HRPC 59 initiated Phase 1b 59 albinterferon alfa 2b 59 MIVI III 59 cathepsin K inhibitor 59 CLIRS 59 OvaRex 59 initiate Phase 59 OVATURE 59 ChronVac C R 59 VEGF Trap 59 Cand5 59 Lovaxin C 59 SparVax TM 59 AeroLEF TM 59 Carfilzomib 59 Iloperidone 59 CRx 59 LibiGel ® 59 Elocalcitol 59 Altastaph 59 Phase Ia Ib 59 PROVENGE sipuleucel T 59 vosaroxin 59 Hepatocellular Carcinoma HCC 59 CTCE 59 CCR5 mAb 59 CIMZIA TM 59 dasatinib Sprycel ® 59 initiate Phase Ib 59 PROPEL trial 59 Elvitegravir 59 non nucleoside HCV 59 Triapine 59 Initiates Phase II 59 dexpramipexole 59 prospective multicenter 59 IMC A# 58 MAXY alpha 58 unblinding 58 Guanilib 58 investigational protease inhibitor 58 ARIKACE 58 Blinatumomab 58 ARDIS 58 Dose escalation 58 lanthanum carbonate 58 Romidepsin 58 Onrigin 58 BR.# 58 SCH # 58 aflibercept 58 generation purine nucleoside 58 MEK inhibitor RDEA# 58 mapatumumab 58 Evamist TM 58 depsipeptide 58 Prostate AdenoCarcinoma Treatment 58 NASDAQ CXSP announced 58 cancer neuroendocrine tumor 58 receptor tyrosine kinase inhibitor 58 Cinquil 58 novel histone deacetylase 58 ocular formulation 58 relapsing multiple sclerosis 58 PERSEUS 58 Plenaxis TM 58 PCK# 58 MYDICAR 58 preclinical studies 58 EchoCRT 58 Kahalalide F 58 AP# [003] 58 HDAC Inhibitor 58 clinicaltrials 58 DSMB 58 Nasdaq PGNX today 58 HCV NS5B polymerase 58 WX UK1 58 EQUIP OB 58 Saforis 58 Phase III Clinical Trials 58 Genz # 58 ofatumumab HuMax CD# 58 Ceplene/IL-2 58 XOMA 3AB 58 Telcyta 58 ALN RSV# 58 oral FTY# 58 ritonavir boosted 58 Zerenex 58 multicentre randomized double 58 Phase IIb kidney transplant 58 refractory chronic lymphocytic 58 ENMD # 58 ALN TTR# 58 multicentre 58 prospectively defined 58 BrachySil ™ 58 Velcade bortezomib 58 Alpharadin 58 TELINTRA 58 PD LID 58 ularitide 58 Anturol TM 58 Pegasys plus Copegus 58 bortezomib Velcade R 58 Cleviprex TM clevidipine 58 BAL# [002] 58 ALN VSP 58 Ostarine 58 Pivotal Trial 58 SAR# [002] 58 MDS AML 58 NSABP 58 anti CD3 monoclonal 58 EndoTAG 58 Genasense ® oblimersen 58 Meets Primary Endpoint 58 celgosivir 58 Sulonex 58 histone deacetylase HDAC inhibitor 58 Phase III VISTA 58 oral formulation 58 DCCR 58 Phase III HEAT 58 HCV polymerase inhibitor 58 Onconase 58 docetaxel Taxotere R 58 VITAL Trial 58 EURIDIS 58 PrevOnco 58 Proxinium TM 58 randomized discontinuation trial 58 Diamyd R 58 APTIVUS r 58 PSN# [001] 58 adecatumumab 58 CLL8 58 albiglutide 58 3 registrational trial 58 REMUNE R 58 GED aPC 58 bendamustine 58 subcutaneous PRO 58 BEMA Granisetron 58 CTA# 58 mg kg BID 58 cangrelor 58 CUSTOM III 58 REOLYSIN ® 58 Menerba 58 inhibitor RG# 58 investigational pan BCR 58 dextromethorphan quinidine 58 IPL# 58 EGS# 58 GSK# [001] 58 Phase #/#a clinical 58 MADIT II 58 azilsartan medoxomil 58 goserelin 58 Genasense ® 58 BrachySil TM 58 oral treprostinil 58 Onalta 58 metastatic castrate resistant 58 Valortim 58 transcriptase inhibitor NNRTI 58 iniparib 58 Phase 2a Clinical Trial 58 refractory acute myeloid 58 PEG INTRON R 58 Phase III metastatic melanoma 58 PEG Interferon lambda 58 RhuDex 58 Metastatic Melanoma 58 secondary efficacy endpoints 58 proteasome inhibitor 58 AZILECT ® 58 REVLIMID lenalidomide 58 cetrorelix pamoate 58 E1 INT TM 58 Amoxicillin PULSYS Phase III 58 Valortim R 58 dexanabinol 58 resminostat 58 AEZS 58 CLORETAZINE TM VNP#M 58 imetelstat GRN#L 58 NXL# 58 plasma pharmacokinetics 58 subcutaneous formulation 58 INCB# [002] 58 histamine dihydrochloride 58 Nitazoxanide 58 incyclinide 58 REG1 Anticoagulation System 58 RG# [001] 58 CA4P 58 Dyloject TM 58 Pralatrexate 58 cell lymphoma CTCL 58 Phase 2b Trial 58 Fodosine 58 triphendiol 58 GLP toxicology 58 Thorough QT 58 Marqibo 58 Tasimelteon 58 Intervention Effectiveness 58 DB# [003] 58 ExTRACT TIMI 58 demonstrated antitumor activity 58 mipomersen 58 Enzastaurin 58 ThermoDox ® clinical 58 randomized crossover 58 ONTARGET 58 Temsirolimus 58 Pemetrexed 58 Phase Ib Clinical Trial 58 Ceflatonin R 58 MAA submission 58 elagolix 58 OLpur TM H2H 58 latrepirdine 58 Parkinson disease levodopa induced 58 Bayer HealthCare Onyx Pharmaceuticals 58 obatoclax 58 docetaxel chemotherapy 58 ganaxolone 58 cobiprostone 58 Phase IIa proof 58 REG2 58 dependent kinase inhibitor 58 efficacy endpoints 58 Factor VIIa 58 Safinamide 58 EVIZON TM squalamine lactate 58 ApoB SNALP 58 pegloticase 58 Oglemilast 58 Denufosol 58 evaluating MGCD# [002] 58 OPT CHF 58 active comparator 58 ancrod 58 DU #b 58 Panzem R 58 eliglustat tartrate 58 ORENCIA R 58 inecalcitol 58 Vectibix panitumumab 58 MIRCERA 58 atacicept 58 TYGACIL 58 Study Evaluating 58 Neuradiab TM 58 randomized controlled clinical 58 relapsed ALL 58 C1 INH 58 aflibercept VEGF Trap 58 refractory metastatic colorectal cancer 58 CRD5 58 CINTREDEKIN BESUDOTOX 58 investigational humanized monoclonal antibody 58 Phase 2a preventative 58 CANCIDAS 58 XIENCE V Stent System 58 GVAX ® 58 Nasdaq MAPP 57 LT NS# 57 BCX# 57 Dasatinib 57 Randomized controlled 57 Hsp# inhibitor 57 fidaxomicin Phase 57 tgAAC# 57 lesinurad 57 evaluating T DM1 57 EmbraceAC 57 antiviral efficacy 57 TO AVOID PREGNANCY WHILE 57 RE LY ® 57 Myelodysplastic Syndrome MDS 57 Raptiva ® 57 randomized controlled clinical trials 57 telaprevir dosed 57 PS# DARA 57 bazedoxifene conjugated estrogens 57 REGN# 57 VQD 57 nab paclitaxel 57 multicentre randomized controlled 57 AVONEX ® 57 controlled multicenter Phase 57 blind randomized controlled 57 VELCADE melphalan 57 ixabepilone 57 alemtuzumab Campath 57 IIa clinical trials 57 tolerability profile 57 danoprevir 57 personalized immunotherapy 57 OMP #R# 57 ORACLE MS 57 Clonicel